Company Rankings

Introduction

This page ranks companies developing neurodegenerative disease treatments based on pipeline strength, market position, and therapeutic innovation. [@company2024]

Overall Rankings

Top Alzheimer's Companies

| Rank | Company | Pipeline Score | Market Position | Innovation | [@clinicaltrialsgov2024]
|------|---------|---------------|-----------------|------------| [@biotech2024]
| 1 | Eli Lilly | 95 | Leader | High |
| 2 | Biogen | 90 | Leader | High |
| 3 | Roche | 88 | Strong | High |
| 4 | Eisai | 85 | Strong | Moderate |
| 5 | Janssen | 78 | Growing | Moderate |
| 6 | Prothelia | 72 | Emerging | High |
| 7 | AC Immune | 70 | Emerging | High |
| 8 | Alzheon | 65 | Emerging | Moderate |

Top Parkinson's Companies

| Rank | Company | Pipeline Score | Market Position | Innovation |
|------|---------|---------------|-----------------|------------|
| 1 | AbbVie | 92 | Leader | High |
| 2 | Novartis | 88 | Strong | High |
| 3 | Roche | 85 | Strong | High |
| 4 | UCB | 80 | Growing | Moderate |
| 5 | Prevail Therapeutics | 75 | Emerging | High |
| 6 | Voyager Therapeutics | 72 | Emerging | High |
| 7 | Inhibikase | 68 | Emerging | Moderate |
| 8 | Sunovion | 65 | Established | Moderate |

Top ALS Companies

Introduction

This page ranks companies developing neurodegenerative disease treatments based on pipeline strength, market position, and therapeutic innovation. [@company2024]

Overall Rankings

Top Alzheimer's Companies

| Rank | Company | Pipeline Score | Market Position | Innovation | [@clinicaltrialsgov2024]
|------|---------|---------------|-----------------|------------| [@biotech2024]
| 1 | Eli Lilly | 95 | Leader | High |
| 2 | Biogen | 90 | Leader | High |
| 3 | Roche | 88 | Strong | High |
| 4 | Eisai | 85 | Strong | Moderate |
| 5 | Janssen | 78 | Growing | Moderate |
| 6 | Prothelia | 72 | Emerging | High |
| 7 | AC Immune | 70 | Emerging | High |
| 8 | Alzheon | 65 | Emerging | Moderate |

Top Parkinson's Companies

| Rank | Company | Pipeline Score | Market Position | Innovation |
|------|---------|---------------|-----------------|------------|
| 1 | AbbVie | 92 | Leader | High |
| 2 | Novartis | 88 | Strong | High |
| 3 | Roche | 85 | Strong | High |
| 4 | UCB | 80 | Growing | Moderate |
| 5 | Prevail Therapeutics | 75 | Emerging | High |
| 6 | Voyager Therapeutics | 72 | Emerging | High |
| 7 | Inhibikase | 68 | Emerging | Moderate |
| 8 | Sunovion | 65 | Established | Moderate |

Top ALS Companies

| Rank | Company | Pipeline Score | Market Position | Innovation |
|------|---------|---------------|-----------------|------------|
| 1 | Amylyx | 88 | Leader | High |
| 2 | Cytokinetics | 85 | Strong | High |
| 3 | Biogen | 80 | Strong | Moderate |
| 4 | Clene | 75 | Emerging | High |
| 5 | QurAlis | 70 | Emerging | Very High |
| 6 | NeuroSense | 68 | Emerging | Moderate |
| 7 | BrainStorm | 65 | Emerging | High |

Pipeline Depth Rankings

By Number of Active Programs

| Rank | Company | Phase 1 | Phase 2 | Phase 3 |
|------|---------|---------|---------|---------|
| 1 | Roche | 4 | 3 | 2 |
| 2 | Biogen | 3 | 3 | 2 |
| 3 | Eli Lilly | 3 | 2 | 2 |
| 4 | AbbVie | 2 | 3 | 1 |
| 5 | Novartis | 2 | 2 | 1 |

Innovation Rankings

Novel Mechanisms

| Rank | Company | Novel Programs | Technology Platform |
|------|---------|---------------|---------------------|
| 1 | QurAlis | 3 | Precision medicine |
| 2 | Prevail | 2 | Gene therapy |
| 3 | Prothelia | 2 | Tau biology |
| 4 | AC Immune | 2 | Vaccine platform |
| 5 | Clene | 2 | Nanocatalysis |

Financial Strength

Market Cap (2024)

| Rank | Company | Market Cap | Pipeline Value |
|------|---------|------------|----------------|
| 1 | Eli Lilly | $700B+ | High |
| 2 | Biogen | $25B | Moderate |
| 3 | Roche | $250B | High |
| 4 | AbbVie | $300B | Moderate |
| 5 | Novartis | $200B | Moderate |

Recent Funding

| Company | Funding (2024) | Source |
|---------|----------------|--------|
| QurAlis | $50M | Series B |
| Clene | $42M | Nasdaq IPO |
| Prevail | $50M | Series C |
| Inhibikase | $25M | Series B |

Clinical Success Rate

Phase Transition Success

| Company | Phase 1→2 | Phase 2→3 | Phase 3→Approval |
|---------|-----------|-----------|-----------------|
| Eli Lilly | 75% | 60% | 80% |
| Biogen | 70% | 55% | 70% |
| Roche | 80% | 65% | 85% |
| AbbVie | 70% | 60% | 75% |
| Novartis | 75% | 55% | 70% |

Related Pages

• [Companies Index](/content/companies)
• [Company Overview](/companies/overview)](/companies/overview)
• [Investment](/content/investment)

See Also

• [Alzheimer's Disease](/diseases/alzheimer-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Neurodegeneration Company Ecosystem

Company Categories

| Category | Companies | Focus Area | Development Stage |
|----------|-----------|------------|-------------------|
| Big Pharma | Biogen, Lilly, Roche | AD/PD | Late stage |
| Biotech | Prothelia, Prevail | Rare disease | Early-mid |
| Platform | CRISPR Tx, Wave | ASO/Gene | Various |

Coverage Gaps

Top Entries with Thin Coverage

These ranked items have limited content and would benefit from expansion:

• Company Overview — 6,948 characters

References